 Jason Christie
Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Purkinje Cells | 9 | 2023 | 70 | 3.960 |
Why?
| | Cerebellum | 11 | 2024 | 224 | 3.560 |
Why?
| | Interneurons | 11 | 2023 | 122 | 2.640 |
Why?
| | Dendrites | 6 | 2021 | 105 | 2.370 |
Why?
| | Cerebellar Cortex | 4 | 2019 | 21 | 2.000 |
Why?
| | Axons | 7 | 2019 | 198 | 1.880 |
Why?
| | Calcium Signaling | 7 | 2021 | 249 | 1.850 |
Why?
| | Action Potentials | 9 | 2021 | 493 | 1.800 |
Why?
| | Presynaptic Terminals | 4 | 2017 | 88 | 1.660 |
Why?
| | Synapses | 5 | 2019 | 427 | 1.540 |
Why?
| | Movement | 4 | 2022 | 278 | 1.290 |
Why?
| | Potassium Channels | 4 | 2017 | 151 | 1.200 |
Why?
| | Neural Inhibition | 3 | 2018 | 169 | 1.180 |
Why?
| | Learning | 3 | 2022 | 409 | 1.140 |
Why?
| | Neuronal Plasticity | 3 | 2021 | 290 | 0.830 |
Why?
| | Patch-Clamp Techniques | 10 | 2018 | 286 | 0.830 |
Why?
| | Olfactory Bulb | 4 | 2006 | 93 | 0.780 |
Why?
| | Synaptic Transmission | 7 | 2022 | 289 | 0.760 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 5 | 2014 | 219 | 0.700 |
Why?
| | Shaw Potassium Channels | 2 | 2017 | 4 | 0.650 |
Why?
| | Olivary Nucleus | 1 | 2019 | 15 | 0.610 |
Why?
| | Motor Activity | 2 | 2021 | 718 | 0.580 |
Why?
| | Mice | 18 | 2024 | 17794 | 0.550 |
Why?
| | Nerve Net | 2 | 2018 | 256 | 0.550 |
Why?
| | Animals | 27 | 2024 | 36951 | 0.550 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 67 | 0.530 |
Why?
| | Microscopy, Fluorescence | 2 | 2015 | 402 | 0.530 |
Why?
| | Functional Neuroimaging | 1 | 2015 | 55 | 0.480 |
Why?
| | Connexins | 2 | 2006 | 48 | 0.470 |
Why?
| | Lung Transplantation | 3 | 2024 | 313 | 0.450 |
Why?
| | Receptors, Presynaptic | 1 | 2014 | 10 | 0.440 |
Why?
| | Psychomotor Performance | 1 | 2017 | 309 | 0.430 |
Why?
| | Calcium | 4 | 2017 | 1200 | 0.410 |
Why?
| | Mice, Transgenic | 4 | 2021 | 2167 | 0.400 |
Why?
| | Excitatory Amino Acid Antagonists | 5 | 2009 | 100 | 0.390 |
Why?
| | Brain Mapping | 1 | 2015 | 503 | 0.390 |
Why?
| | Behavior, Animal | 1 | 2015 | 501 | 0.380 |
Why?
| | Reflex, Vestibulo-Ocular | 2 | 2022 | 10 | 0.380 |
Why?
| | Ion Channel Gating | 2 | 2009 | 90 | 0.380 |
Why?
| | Periodicity | 2 | 2022 | 58 | 0.320 |
Why?
| | Pyramidal Cells | 1 | 2009 | 74 | 0.300 |
Why?
| | Ion Channels | 1 | 2009 | 133 | 0.300 |
Why?
| | Optogenetics | 2 | 2021 | 108 | 0.290 |
Why?
| | Calcium Channels | 1 | 2008 | 159 | 0.280 |
Why?
| | Touch Perception | 2 | 2018 | 17 | 0.270 |
Why?
| | Touch | 2 | 2018 | 36 | 0.270 |
Why?
| | Haploinsufficiency | 2 | 2024 | 56 | 0.260 |
Why?
| | In Vitro Techniques | 5 | 2009 | 1092 | 0.260 |
Why?
| | Receptors, AMPA | 4 | 2014 | 141 | 0.250 |
Why?
| | Evoked Potentials, Somatosensory | 1 | 2006 | 33 | 0.250 |
Why?
| | Olfactory Pathways | 1 | 2006 | 36 | 0.250 |
Why?
| | Rats, Sprague-Dawley | 6 | 2010 | 2487 | 0.240 |
Why?
| | Neurons, Afferent | 1 | 2006 | 97 | 0.240 |
Why?
| | Rats | 7 | 2010 | 5648 | 0.230 |
Why?
| | Membrane Potentials | 4 | 2009 | 284 | 0.230 |
Why?
| | Signal Transduction | 2 | 2017 | 5081 | 0.230 |
Why?
| | DiGeorge Syndrome | 1 | 2024 | 32 | 0.230 |
Why?
| | T-Box Domain Proteins | 1 | 2024 | 98 | 0.220 |
Why?
| | Cerebellar Vermis | 1 | 2023 | 5 | 0.210 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2018 | 124 | 0.210 |
Why?
| | Microscopy, Confocal | 2 | 2019 | 325 | 0.210 |
Why?
| | Mice, Inbred C57BL | 4 | 2018 | 5764 | 0.210 |
Why?
| | Glutamic Acid | 4 | 2008 | 246 | 0.200 |
Why?
| | Neurons | 3 | 2018 | 1590 | 0.180 |
Why?
| | Receptors, GABA-A | 3 | 2022 | 142 | 0.180 |
Why?
| | Gold Colloid | 1 | 2021 | 1 | 0.180 |
Why?
| | Channelrhodopsins | 1 | 2021 | 16 | 0.180 |
Why?
| | Graft Survival | 1 | 2024 | 536 | 0.170 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2022 | 89 | 0.170 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2021 | 45 | 0.170 |
Why?
| | Transplants | 1 | 2021 | 36 | 0.170 |
Why?
| | Electric Stimulation | 3 | 2009 | 264 | 0.170 |
Why?
| | Tissue Donors | 1 | 2024 | 425 | 0.170 |
Why?
| | Microscopy, Electron | 1 | 2021 | 443 | 0.170 |
Why?
| | Hydroxychloroquine | 1 | 2020 | 58 | 0.170 |
Why?
| | Hippocampus | 1 | 2006 | 895 | 0.170 |
Why?
| | Endocannabinoids | 1 | 2021 | 63 | 0.170 |
Why?
| | Metal Nanoparticles | 1 | 2021 | 83 | 0.160 |
Why?
| | Wakefulness | 1 | 2021 | 125 | 0.160 |
Why?
| | Graft Rejection | 1 | 2024 | 624 | 0.160 |
Why?
| | Tissue and Organ Procurement | 1 | 2024 | 321 | 0.160 |
Why?
| | Piperidines | 1 | 2021 | 206 | 0.160 |
Why?
| | Excitatory Amino Acid Agonists | 2 | 2009 | 39 | 0.150 |
Why?
| | Physical Stimulation | 1 | 2019 | 65 | 0.150 |
Why?
| | ras GTPase-Activating Proteins | 1 | 2018 | 15 | 0.150 |
Why?
| | Male | 11 | 2024 | 67906 | 0.150 |
Why?
| | Water | 1 | 2022 | 461 | 0.150 |
Why?
| | Somatosensory Cortex | 1 | 2018 | 35 | 0.150 |
Why?
| | Sensation Disorders | 1 | 2018 | 37 | 0.150 |
Why?
| | Evoked Potentials, Motor | 1 | 2018 | 46 | 0.150 |
Why?
| | Reperfusion Injury | 1 | 2021 | 279 | 0.140 |
Why?
| | Lung Injury | 1 | 2021 | 219 | 0.140 |
Why?
| | Photic Stimulation | 1 | 2019 | 241 | 0.140 |
Why?
| | Acoustic Stimulation | 1 | 2019 | 312 | 0.140 |
Why?
| | Pyrazoles | 1 | 2021 | 424 | 0.140 |
Why?
| | Neural Pathways | 1 | 2019 | 296 | 0.130 |
Why?
| | Tongue | 1 | 2017 | 81 | 0.130 |
Why?
| | Female | 9 | 2024 | 73465 | 0.130 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2021 | 754 | 0.130 |
Why?
| | Quinoxalines | 2 | 2009 | 66 | 0.130 |
Why?
| | Primary Graft Dysfunction | 1 | 2016 | 32 | 0.120 |
Why?
| | Lipoproteins, HDL | 1 | 2016 | 77 | 0.120 |
Why?
| | Drinking Behavior | 1 | 2015 | 10 | 0.120 |
Why?
| | Vibrissae | 1 | 2015 | 10 | 0.120 |
Why?
| | Protein Kinase C | 1 | 2017 | 261 | 0.120 |
Why?
| | Shaker Superfamily of Potassium Channels | 1 | 2014 | 4 | 0.110 |
Why?
| | Cholesterol | 1 | 2016 | 410 | 0.110 |
Why?
| | Electrophysiological Phenomena | 1 | 2014 | 58 | 0.110 |
Why?
| | Autoantibodies | 1 | 2021 | 1497 | 0.100 |
Why?
| | Fluorescent Dyes | 1 | 2014 | 321 | 0.100 |
Why?
| | 2-Amino-5-phosphonovalerate | 2 | 2003 | 10 | 0.090 |
Why?
| | Brain | 2 | 2021 | 2677 | 0.090 |
Why?
| | Egtazic Acid | 1 | 2010 | 40 | 0.090 |
Why?
| | Coronary Artery Disease | 1 | 2016 | 698 | 0.080 |
Why?
| | Heart Transplantation | 1 | 2016 | 755 | 0.080 |
Why?
| | Iontophoresis | 1 | 2009 | 13 | 0.080 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1738 | 0.080 |
Why?
| | N-Methylaspartate | 1 | 2009 | 40 | 0.080 |
Why?
| | Glutamates | 1 | 2009 | 59 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2021 | 2659 | 0.080 |
Why?
| | Organ Culture Techniques | 1 | 2008 | 156 | 0.070 |
Why?
| | Long-Term Synaptic Depression | 1 | 2008 | 56 | 0.070 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2009 | 198 | 0.070 |
Why?
| | Animals, Newborn | 1 | 2009 | 844 | 0.070 |
Why?
| | Piperazines | 1 | 2009 | 350 | 0.070 |
Why?
| | Indoles | 1 | 2009 | 412 | 0.060 |
Why?
| | Cerebral Cortex | 1 | 2009 | 433 | 0.060 |
Why?
| | Synaptic Vesicles | 1 | 2006 | 44 | 0.060 |
Why?
| | Gap Junctions | 1 | 2005 | 59 | 0.060 |
Why?
| | Temporal Bone | 1 | 2024 | 45 | 0.060 |
Why?
| | Osteoblasts | 1 | 2024 | 126 | 0.050 |
Why?
| | Long-Term Potentiation | 1 | 2006 | 198 | 0.050 |
Why?
| | Skull | 1 | 2024 | 139 | 0.050 |
Why?
| | 4-Aminopyridine | 1 | 2003 | 24 | 0.050 |
Why?
| | Potassium Channel Blockers | 1 | 2003 | 37 | 0.050 |
Why?
| | Tetrodotoxin | 1 | 2003 | 39 | 0.050 |
Why?
| | Pyridazines | 1 | 2003 | 56 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4295 | 0.050 |
Why?
| | Chondrocytes | 1 | 2024 | 212 | 0.050 |
Why?
| | Memory Disorders | 1 | 2023 | 164 | 0.050 |
Why?
| | Mice, Inbred mdx | 1 | 2022 | 12 | 0.050 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2021 | 25 | 0.050 |
Why?
| | Receptor, Endothelin A | 1 | 2021 | 65 | 0.040 |
Why?
| | Bronchiolitis Obliterans | 1 | 2021 | 69 | 0.040 |
Why?
| | Glycosylation | 1 | 2021 | 151 | 0.040 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2001 | 19 | 0.040 |
Why?
| | GABA Antagonists | 1 | 2001 | 35 | 0.040 |
Why?
| | Complement Inactivating Agents | 1 | 2021 | 63 | 0.040 |
Why?
| | Transplantation, Homologous | 1 | 2021 | 416 | 0.040 |
Why?
| | Treatment Failure | 1 | 2020 | 356 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 289 | 0.040 |
Why?
| | Humans | 8 | 2024 | 137782 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2006 | 4193 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2005 | 3018 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2024 | 1991 | 0.030 |
Why?
| | Binding Sites | 1 | 2000 | 1303 | 0.030 |
Why?
| | Allografts | 1 | 2016 | 146 | 0.030 |
Why?
| | Prognosis | 1 | 2024 | 4039 | 0.030 |
Why?
| | Ultrasonography, Interventional | 1 | 2016 | 143 | 0.030 |
Why?
| | Lung Diseases, Interstitial | 1 | 2021 | 642 | 0.030 |
Why?
| | Lung Diseases | 1 | 2021 | 767 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2024 | 5136 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3461 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2016 | 317 | 0.030 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 1042 | 0.030 |
Why?
| | Global Health | 1 | 2016 | 386 | 0.030 |
Why?
| | Survival Rate | 1 | 2016 | 1973 | 0.020 |
Why?
| | Cognition | 1 | 2018 | 1157 | 0.020 |
Why?
| | Middle Aged | 2 | 2024 | 33554 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2041 | 0.020 |
Why?
| | Risk Factors | 1 | 2024 | 10407 | 0.020 |
Why?
| | Adult | 2 | 2024 | 38023 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2760 | 0.020 |
Why?
| | Biomarkers | 1 | 2016 | 4154 | 0.010 |
Why?
| | Aged | 1 | 2020 | 24001 | 0.010 |
Why?
|
|
Christie's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|